NCT03127605|Unknown
Inotuzumab Ozogamicin - PF-05208773
1 other identifier
B193
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredApr 2017
Brief Summary
Inotuzumab Ozogamicin Expanded Access Program
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 20, 2017
Completed5 days until next milestone
First Posted
Study publicly available on registry
April 25, 2017
CompletedLast Updated
May 18, 2020
Status Verified
May 1, 2020
First QC Date
April 20, 2017
Last Update Submit
May 14, 2020
Interventions
Also known as: PF-05208773
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
MeSH Terms
Interventions
Inotuzumab Ozogamicin
Intervention Hierarchy (Ancestors)
CalicheamicinsAminoglycosidesGlycosidesCarbohydratesAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 20, 2017
First Posted
April 25, 2017
Last Updated
May 18, 2020
Record last verified: 2020-05